Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 9 Meters Biopharma Inc NMTRQ

Healthcare
9 Meters Biopharma, Inc. has ceased operations. The Company has filed a voluntary petition for relief under provisions of Chapter 7 of Title 11 of the United States Code (the Bankruptcy Code) in the United States Bankruptcy Court for the Eastern District of North Carolina.

Recent & Breaking News (GREY:NMTRQ)

9 Meters Biopharma Announces Debt Facility to Support Phase 3 Study of Vurolenatide for Short Bowel Syndrome

Accesswire June 30, 2022

9 Meters Biopharma Announces Positive Preliminary Results from Phase 2 Study of Vurolenatide in Short Bowel Syndrome

Accesswire June 30, 2022

9 Meters Biopharma Announces Interim Analysis of Phase 3 Study of Larazotide for Celiac Disease Does Not Support Trial Continuation

Accesswire June 21, 2022

9 Meters Biopharma to Participate in the 2022 BIO International Convention

Accesswire June 13, 2022

9 Meters Biopharma to Exhibit at Digestive Disease Week 2022

Accesswire May 19, 2022

9 Meters Biopharma Presents Preclinical Data at the 2022 American Thoracic Society International Conference on the Use of Larazotide in Idiopathic Pulmonary Fibrosis

Accesswire May 18, 2022

9 Meters Biopharma Provides Business Update and Reports Financial Results for First Quarter 2022

Accesswire May 16, 2022

9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium

Accesswire May 5, 2022

9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease

Accesswire April 20, 2022

9 Meters Biopharma Announces Allowance of Patent for Anti-GIP Monoclonal Antibody NM-136 for the Treatment of Serious Metabolic Conditions

Accesswire April 13, 2022

9 Meters Biopharma Provides Business Update and Reports Financial Results for Fourth Quarter and Full Year 2021

Accesswire March 23, 2022

9 Meters Biopharma to Present at the Maxim Group 2022 Virtual Growth Conference

Accesswire March 21, 2022

9 Meters Biopharma to Present at the Oppenheimer 32nd Annual Healthcare Conference

Accesswire March 9, 2022

9 Meters Biopharma Announces a Collaboration with NYU Langone Health Investigating NM-102 as a Potential Treatment for an Autoimmune Disorder

Accesswire March 2, 2022

9 Meters Biopharma Provides Clinical Update on Late-Stage Pipeline Products Vurolenatide for Short Bowel Syndrome and Larazotide for Celiac Disease

Accesswire February 28, 2022

9 Meters Biopharma Announces Publication of Data on Larazotide for the Treatment of Multisystem Inflammatory Syndrome in Children (MIS-C)

Accesswire February 25, 2022

9 Meters Biopharma to Present at the 2022 BIO CEO & Investor Conference

Accesswire February 9, 2022

9 Meters Biopharma Announces Allowance of Patent for NM-102 in Combination with Immune Checkpoint Inhibitors

Accesswire January 24, 2022

9 Meters Biopharma Appoints Bethany Sensenig as Chief Financial Officer

Accesswire January 18, 2022

9 Meters Biopharma, Inc. to Participate in the following Virtual January Investor Conferences

Accesswire January 4, 2022